Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 18/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12199354 | 1.00 | SCD (1.00) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2480611 | 1.00 | SCD (1.00) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL31243 | 0.93 | SCD (1.00) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2753553 | 0.89 | SCD (0.93) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4919654 | 0.89 | SCD (0.88) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4913650 | 0.89 | SCD (0.88) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4920310 | 0.89 | SCD (0.88) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16554145 | 0.89 | SCD (0.88) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL16681363 | 0.89 | SCD (0.88) | SCDNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4918742 | 0.88 | SCD (0.86) | SCDNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120020881-A1 | Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243846-A1 | BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA | APP, APBA1, BACE1 | SCD 2053/4885NPC1 473/4885RAB9A 2966/4885 |
| US-20120020881-A1 | Triaryl-sulphonium compounds, kit and methods for labeling positron emitting isotopes | KIT, STS, TST | SCD 2140/4885NPC1 634/4885RAB9A 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.